Citations 2
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.
Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574
Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.
Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Makiya, Michelle , Khoury, Paneez , Kuang, Fei Li , Mata, Alexis Dominique , Mahmood, Sana , Bowman, Abbie, Kovacs, Nicholas A. , Holland, Nicole, Dyer, Anne‐Marie , Akuthota, Praveen , Gleich, Gerald J. , Langford, Carol A. , Weller, Peter F. , Makiya, Michelle A , Wetzler, Lauren , Dyer, Anne-Marie , Bochner, Bruce S , Chinchilli, Vernon M , Gleich, Gerald J , Merkel, Peter A , Specks, Ulrich , Weller, Peter F , Wechsler, Michael E , Prussin, Calman , Klion, Amy D , Mahmood, Sana, Espinoza, David, Kovacs, Nicholas, Brown, Thomas , Ware, JeanAnne M. , Bochner, Bruce S. , Merkel, Peter A. , Specks, Ulrich , Fay, Michael P. , Klion, Amy D.
Allergy | August 16, 2022 | Volume: 78 | Issue: 1 | Pages: 258-269
AbstractBackgroundBiomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect tissue eosinophilia or eosinophil activation. Therefore, the aims of this study were to compare the reliability of plasma and urine eosinophil major basic protein 1, eosinophil cationic protein, eosinophil‐derived neurotoxin (EDN), and eosinophil peroxidase measurement and to evaluate the usefulness of eosinophil granule protein (EGP) measurement for the assessment of disease activity in patients with eosinophil‐associated diseases treated with mepolizumab, benralizumab, or dexpramipexole.MethodsEosinophil granule protein concentrations were measured in serum, plasma, and urine from healthy volunteers and patients with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a multiplex assay.ResultsUrine EGP concentrations remained stable, whereas serum and plasma EGP concentrations increased significantly with delayed processing. Plasma (p) EDN, but not urine (u) EDN, concentration correlated with AEC and negatively correlated with prednisone dose. Both pEDN and uEDN decreased significantly following treatment of HES patients with benralizumab and EGPA patients with mepolizumab. uEDN appeared to increase with clinical relapse in both patient groups.ConclusionsMeasurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA.